If fewer than 5 days have passed since your scheduled injection, take your normal dose immediately and adjust your schedule forward
Patients taking GLP-1 drugs were 38% to 50% less likely to progress to stage 4 metastatic cancer in four major cancer types
Adverse Reactions (6.1).] Maintenance of Sitagliptin During Initiation and Titration of Insulin Glargine A total of 746 patients with type 2 diabetes (mean baseline HbA1C 8.8%, disease duration 10.8 years) participated in a 30-week, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of continuing sitagliptin during the initiation and uptitration of insulin glargine
10.3389/fimmu.2022.997578 26 ChengM
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
For women who prefer not to self-inject, or who have found it difficult to build an injection routine into their day, Foundayo offers a meaningful alternative supported by FDA approval